Form 4: Avidity CMO Sells $3.48M in Stock

Avidity Biosciences' Chief Medical Officer, Steven George Hughes, sold over $3.48 million worth of company stock after exercising options, reducing his direct beneficial ownership.

Summary

• Chief Medical Officer Steven George Hughes sold a total of 81,434 shares of Avidity Biosciences, Inc. common stock on August 6, 2025.
• The sales were executed at a weighted-average price of $42.7373 per share, generating approximately $3.48 million in proceeds.
• Of the shares sold, 47,451 were acquired through the exercise of stock options at various exercise prices ranging from $6.57 to $22.47 per share.
• An additional 33,983 shares were sold from existing direct holdings.
• All transactions were conducted pursuant to a Rule 10b5-1 trading plan previously adopted on June 12, 2024.
• Following these transactions, Mr. Hughes' direct beneficial ownership stands at 38,867 shares.

Sentiment

Score: 5

Explanation: The sale by a key executive, while reducing direct ownership, was conducted under a pre-arranged 10b5-1 plan, which is a common practice for liquidity and diversification, mitigating negative sentiment. The significant profit from option exercises also indicates the stock's appreciation.

Positives

• The officer exercised stock options at significantly lower prices (ranging from $6.57 to $22.47) compared to the sale price ($42.7373), indicating substantial personal gain from the company's stock appreciation.
• The transactions were pre-planned under a Rule 10b5-1 trading plan, suggesting the sales were for personal liquidity and diversification rather than based on new, non-public information.

Negatives

• A significant reduction in direct beneficial ownership by a key executive (Chief Medical Officer) through the sale of 81,434 shares.
• The sale included 33,983 shares from existing holdings, not solely shares acquired through option exercises, which represents a net decrease in the executive's stake.

Stakeholder Impact

• Shareholders: May view the executive's sale as a signal, but the 10b5-1 plan context provides a mitigating factor. The reduction in direct ownership could be seen as a decrease in alignment with shareholder interests.

Key Dates

Recommendation

While a significant insider sale can be a negative signal, the execution under a Rule 10b5-1 plan suggests it is a pre-planned liquidity event rather than a reaction to new negative information. Without further financial or strategic updates from the company, a Form 4 alone is insufficient to warrant a strong buy or sell recommendation, thus a 'hold' is appropriate for existing investors. New investors would need to consider broader company fundamentals.

Keywords

Avidity Biosciences, RNA, insider trading, Form 4, stock options, stock sale, Steven George Hughes, Chief Medical Officer, 10b5-1 plan, beneficial ownership